1Athar U,Gentile T C.Treatment options for metastatic renal cell carcinoma:a review[J].Can J Urol,2008,15(2):3954-3966.
2Kollender Y,Bickels J,Price W M,et al.Metastatic renal cell carcinoma of bone:indications and technique of surgical intervention[J].J Urol,2000,164(5):1505-1508.
3Motzer R J,Escudier B,Tomczak P,et al.Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma:overall survival analysis and updated results from a randomised phase 3trial[J].Lancet Oncol,2013,14(6):552-562.
4Mckay R R,Kroeger N,Xie W,et al.Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy[J].Eur Urol,2014,65(3):577-584.
5Mundy G R.Metastasis to bone:causes,consequences and therapeutic opportunities[J].Nat Rev Cancer,2002,2(8):584-593.
6Keizman D,Ish-Shalom M,Pili R,et al.Bisphosphonates combined with sunitinib may improve the response rate,progression free survival and overall survival of patients with bone metastases from renal cell carcinoma[J].Eur J Cancer,2012,48(7):1031-1037.
7Moriceau G,Ory B,Mitrofan L,et al.Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001(Everolimus):pivotal role of the prenylation process[J].Cancer Res,2010,70(24):10329-10339.
